Pakistan Business News API

{
    "totalArticles": 3396900,
    "articles": [
        {
            "title": "RATIONALE-306 Subgroup Data Further Support First-line Tislelizumab/Chemo in Locally Advanced ESCC",
            "description": "Tislelizumab plus chemotherapy improves efficacy vs chemotherapy alone in locally advanced ESCC, including those with PD-L1 TAP of 5% or higher.",
            "content": "Frontline Tislelizumab Plus Chemo in\nLocally Advanced ESCC | Image Credit: ©\nAshling Wahner & MJH Life Sciences Using AI\nThe frontline combination of tislelizumab-jsgr (Tevimbra) plus chemotherapy demonstrated efficacy improvements over chemotherapy ... [7731 chars]",
            "url": "https://www.onclive.com/view/rationale-306-subgroup-data-further-support-first-line-tislelizumab-chemo-in-locally-advanced-escc",
            "image": "https://cdn.sanity.io/images/0vv8moc6/onclive/f45b0e87c5a50a006c62f50f04da2597b74720e5-1920x1080.jpg?fit=crop&auto=format",
            "publishedAt": "2025-07-05T20:56:56Z",
            "source": {
                "name": "OncLive",
                "url": "https://www.onclive.com"
            }
        },
        {
            "title": "Qantas attack reveals one phone call is all it takes to crack cybersecurity’s weakest link: humans",
            "description": "Other sectors also at risk from attacks, including healthcare, finance and telecommunications, expert warns",
            "content": "All it can take is a phone call. That’s what Qantas learned this week when the personal information of up to 6 million customers was stolen by cybercriminals after attackers targeted an offshore IT call centre, enabling them to access a third-party s... [6743 chars]",
            "url": "https://www.theguardian.com/business/2025/jul/06/qantas-attack-reveals-one-phone-call-is-all-it-takes-to-crack-cybersecuritys-weakest-link-humans",
            "image": "https://i.guim.co.uk/img/media/d2728753a7fafb119cb9fabb5b20e81dac970aea/319_0_4583_3667/master/4583.jpg?width=1200&height=630&quality=85&auto=format&fit=crop&overlay-align=bottom%2Cleft&overlay-width=100p&overlay-base64=L2ltZy9zdGF0aWMvb3ZlcmxheXMvdGctZGVmYXVsdC5wbmc&enable=upscale&s=ac180983c365bc74e75be0a1040ddb58",
            "publishedAt": "2025-07-05T20:02:00Z",
            "source": {
                "name": "The Guardian",
                "url": "https://www.theguardian.com"
            }
        },
        {
            "title": "The OncFive: Top Oncology Articles for the Week of 6/29",
            "description": "The FDA grants approval to sunvozertinib in NSCLC and linvoseltamab in myeloma and removes REMS requirements for approved CAR T-cell therapies.",
            "content": "Welcome to OncLive®’s OncFive!\nEvery week, we bring you a quick roundup of the 5 top stories from the world of oncology—ranging from pivotal regulatory decisions to key pipeline updates to expert insights on breakthroughs that are moving the needle i... [5322 chars]",
            "url": "https://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-6-29",
            "image": "https://cdn.sanity.io/images/0vv8moc6/onclive/61826f28ee29ddeff286add711a953f78ff1739f-800x800.jpg?fit=crop&auto=format",
            "publishedAt": "2025-07-05T19:09:05Z",
            "source": {
                "name": "OncLive",
                "url": "https://www.onclive.com"
            }
        }
    ]
}